These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26957200)

  • 1. Antibody-Based Preventive and Therapeutic Strategies Against HIV.
    Fabra-Garcia A; Beltran C; Sanchez-Merino V; Yuste E
    Curr HIV Res; 2016; 14(3):260-9. PubMed ID: 26957200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies.
    Lewis GK
    Curr HIV Res; 2013 Jul; 11(5):354-64. PubMed ID: 24191940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2984-7. PubMed ID: 23602538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
    Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
    PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
    Wren L; Kent SJ
    Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody B cell responses in HIV-1 infection.
    Mouquet H
    Trends Immunol; 2014 Nov; 35(11):549-61. PubMed ID: 25240985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Fc receptors in HIV prevention and therapy.
    Boesch AW; Brown EP; Ackerman ME
    Immunol Rev; 2015 Nov; 268(1):296-310. PubMed ID: 26497529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering broadly neutralizing antibodies for HIV prevention and therapy.
    Hua CK; Ackerman ME
    Adv Drug Deliv Rev; 2016 Aug; 103():157-173. PubMed ID: 26827912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection.
    Parsons MS; Le Grand R; Kent SJ
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29912167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
    Brady JM; Baltimore D; Balazs AB
    Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.
    Rossignol E; Alter G; Julg B
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):22-31. PubMed ID: 33586772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.